Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3 '-Deoxy-3 '-[F-18]-Fluorothymidine Positron Emission Tomography
Keywords: Met Mediated Resistance, Egfr, Tyrosine Kinase, Inhibitors, Non Small Cell, Lung, Cancer, Fluorothymidine, Animals
, Antineoplastic Agents Pharmacology
, Blotting, Western
, Carcinoma, Non-Small-Cell Lung Radionuclide Imaging
, Cell Line, Tumor
, Drug Resistance, Neoplasm Genetics
, Female
, Fluorine Radioisotopes Diagnostic Use
, Humans
, Lung Neoplasms Radionuclide Imaging
, Mice
, Inbred Balb C
, Nude
, Positron-Emission Tomography Methods
, Protein Kinase Inhibitors Pharmacology
, Proto-Oncogene Proteins C-Met Genetics
, Pyrazoles Pharmacology
, Pyridines Pharmacology
, Quinazolines Pharmacology
, Rna Interference
, Radiopharmaceuticals Diagnostic Use
, Receptor, Epidermal Growth Factor Antagonists, Xenograft Model Antitumor Assays, Crizotinib, Epidermal Growth Factor Receptor, Erlotinib, Met Protein, Pyrazole Derivative, Pyridine Derivative, Quinazoline Derivative, Radiopharmaceutical Agent, Scatter Factor Receptor, Antagonists And Inhibitors, Bagg Albino Mouse, Drug Screening, Lung Tumor, Non Small Cell Lung Cancer, Nude Mouse, Positron Emission Tomography, Procedures, Scintiscanning, Tumor Cell Line, Western Blotting, Non-Small-Cell Lung Diagnostic Imaging
, Erlotinib Hydrochloride
, Lung Neoplasms Diagnostic Imaging,
Affiliations: *** IBB - CNR ***
Institute of Biostructures and Bioimages, National Research CouncilNaples, Italy
CEINGE-Advanced BiotechnologiesNaples, Italy
Department of Advanced Biomedical Sciences, University Federico II, Via Pansini 5, Edificio 10Napoli, Italy
References: Pao, W., Chmielecki, J., Rational, biologically based treatment of EGFRmutant non-small-cell lung cancer (2010) Nat Rev Cancer, 10, pp. 760-77
Sequist, L.V., Martins, R.G., Spigel, D., Grunberg, S.M., Spira, A., Janne, P.A., First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations (2008) J Clin Oncol, 26, pp. 2442-2449
Engelman, J.A., Janne, P.A., Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer (2008) Clin Cancer Res, 14, pp. 2895-2899
Ohashi, K., Maruvka, Y.E., Michor, F., Pao, W., Epidermal growth factor receptor tyrosine kinase inhibitor-resistant disease (2013) J Clin Oncol, 31, pp. 1070-1080
Pao, W., Miller, V.A., Politi, K.A., Riely, G.J., Somwar, R., Zakowski, M.F., Acquired resistance of lung adenocarcinomas to gefitinib or erlotinib is associated with a second mutation in the EGFR kinase domain (2005) PLoS Med, 2, p. e73
Engelman, J.A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J.O., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (2007) Science, 316, pp. 1039-1043
Sequist, L.V., Waltman, B.A., Dias-Santagata, D., Digumarthy, S., Turke, A.B., Fidias, P., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (2011) Sci Transl Med, 3, p. 75ra26
Zannetti, A., Iommelli, F., Speranza, A., Salvatore, M., Del Vecchio, S., 30-deoxy-30-18F-fluorothymidine PET/CT to guide therapy with epidermal growth factor receptor antagonists and Bcl-xL inhibitors in non-small cell lung cancer (2012) J Nucl Med, 53, pp. 443-450
Blumenschein, G.R., Jr., Mills, G.B., Gonzalez-Angulo, A.M., Targeting the hepatocyte growth factor-cMET axis in cancer therapy (2012) J Clin Oncol, 30, pp. 3287-3296
Sadiq, A.A., Salgia, R., MET as a possible target for non-small-cell lung cancer (2013) J Clin Oncol, 31, pp. 1089-1096
Karamouzis, M.V., Konstantinopoulos, P.A., Papavassiliou, A.G., Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors (2009) Lancet Oncol, 10, pp. 709-717
Cappuzzo, F., Marchetti, A., Skokan, M., Rossi, E., Gajapathy, S., Felicioni, L., Increased MET gene copy number negatively affects survival of surgically resected non-small-cell lung cancer patients (2009) J Clin Oncol, 27, pp. 1667-1674
Zhao, X., Weir, B.A., Laframboise, T., Lin, M., Beroukhim, R., Garraway, L., Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis (2005) Cancer Res, 65, pp. 5561-5570
Kubo, T., Yamamoto, H., Lockwood, W.W., Valencia, I., Soh, J., Peyton, M., MET gene amplification or EGFR mutation activate MET in lung cancers untreated with EGFR tyrosine kinase inhibitors (2009) Int J Cancer, 124, pp. 1778-1784
Bean, J., Brennan, C., Shih, J.Y., Riely, G., Viale, A., Wang, L., MET amplification occurs with or without T790M mutations in EGFR mutant lung tumors with acquired resistance to gefitinib or erlotinib (2007) Proc Natl Acad Sci USA, 104, pp. 20932-20937
Kuang, Y., Rogers, A., Yeap, B.Y., Wangl Makrigiorgos, M., Vetrand, K., Noninvasive detection of EGFR T790M in gefitinib or erlotinib resistant non-small cell lung cancer (2009) Clin Cancer Res, 15, pp. 2630-2636
Rosell, R., Molina, M.A., Costa, C., Simonetti, S., Gimenez-Capitan, A., Bertran-Alamillo, J., Pretreatment EGFR T790M mutation and BRCA1 mRNA expression in erlotinib-treated advanced non-smallcell lung cancer patients with EGFR mutations (2011) Clin Cancer Res, 17, pp. 1160-1168
Sharma, S.V., Bell, D.W., Settleman, J., Haber, D.A., Epidermal growth factor receptor mutations in lung cancer (2007) Nat Rev Cancer, 7, pp. 169-181
Shaw, A.T., Yasothan, U., Kirkpatrick, P., Crizotinib (2011) Nat Rev Drug Discov, 10, pp. 897-898
Cui, J.J., Tran-Dube, M., Shen, H., Nambu, M., Kung, P.P., Pairish, M., Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) (2011) J Med Chem, 54, pp. 6342-6363
Padda, S., Neal, J.W., Wakelee, H.A., MET inhibitors in combination with other therapies in non-small cell lung cancer (2012) Transl Lung Cancer Res, 1, pp. 238-253
Oh, S.J., Mosdzianowski, C., Chi, D.Y., Kim, J.Y., Kang, S.H., Ryu, J.S., Fully automated synthesis system of 30-deoxy-30-[18F]fluorothymidine (2004) Nucl Med Biol, 31, pp. 803-809
Fonti, R., Larobina, M., Del Vecchio, S., De Luca, S., Fabbricini, R., Catalano, L., Metabolic tumor volume assessed by 18F-FDG PET/CT for the prediction of outcome in patients with multiple myeloma (2012) J Nucl Med, 53, pp. 1829-1835
Zannetti, A., Del Vecchio, S., Carriero, M.V., Fonti, R., Franco, P., Botti, G., Coordinate up-regulation of Sp1 DNA-binding activity and urokinase receptor expression in breast carcinoma (2000) Cancer Res, 60, pp. 1546-1551
Ma, P.C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M.S., Nallasura, V., Fox, E.A., Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer (2005) Cancer Res, 65, pp. 1479-1488
Pao, W., Girard, N., New driver mutations in non-small-cell lung cancer (2011) Lancet Oncol, 12, pp. 175-180
Gherardi, E., BirchmeierW,Birchmeier C,VandeWoude G.TargetingMET in cancer: Rationale and progress (2012) Nat Rev Cancer, 12, pp. 89-103
Sohn, H.J., Yang, Y.J., Ryu, J.S., Oh, S.J., Im, K.C., Moon, D.H., [18F] Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung (2008) Clin Cancer Res, 14, pp. 7423-7429
Xu, L., Kikuchi, E., Xu, C., Ebi, H., Ercan, D., Cheng, K.A., Combined EGFR/MET or EGFR/HSP90 inhibition is effective in the treatment of lung cancers codriven by mutant EGFR containing T790M and MET (2012) Cancer Res, 72, pp. 3302-3311
Iommelli, F., De Rosa, V., Fonti, R., Del Vecchio, S., Molecular imaging for detection of sensitivity and resistance to EGFR tyrosine kinase inhibitors in non-small cell lung cancer (2014) Clin Transl Imaging, 2, pp. 43-53
Peters, S., Adjei, A.A., Gridelli, C., Reck, M., Kerr, K., Felip, E., Metastatic non-small-cell lung cancer (NSCLC): ESMO Clinical Practice Guidelines for diagnosis, treatment and follow-up (2012) Ann Oncol, 23, pp. vii56-64
Pao, W., Kris, M.G., Iafrate, A.J., Ladanyi, M., Janne, P.A., Wistuba, I.I., Integration of molecular profiling into the lung cancer clinic (2009) Clin Cancer Res, 15, pp. 5317-5322
Sequist, L. V., Martins, R. G., Spigel, D., Grunberg, S. M., Spira, A., Janne, P. A., First-line gefitinib in patients with advanced non-small-cell lung cancer harboring somatic EGFR mutations (2008) J Clin Oncol, 26, pp. 2442-2449
Engelman, J. A., Janne, P. A., Mechanisms of acquired resistance to epidermal growth factor receptor tyrosine kinase inhibitors in non-small cell lung cancer (2008) Clin Cancer Res, 14, pp. 2895-2899
Engelman, J. A., Zejnullahu, K., Mitsudomi, T., Song, Y., Hyland, C., Park, J. O., MET amplification leads to gefitinib resistance in lung cancer by activating ERBB3 signaling (2007) Science, 316, pp. 1039-1043
Sequist, L. V., Waltman, B. A., Dias-Santagata, D., Digumarthy, S., Turke, A. B., Fidias, P., Genotypic and histological evolution of lung cancers acquiring resistance to EGFR inhibitors (2011) Sci Transl Med, 3, p. 75ra26
Blumenschein, G. R., Jr., Mills, G. B., Gonzalez-Angulo, A. M., Targeting the hepatocyte growth factor-cMET axis in cancer therapy (2012) J Clin Oncol, 30, pp. 3287-3296
Sadiq, A. A., Salgia, R., MET as a possible target for non-small-cell lung cancer (2013) J Clin Oncol, 31, pp. 1089-1096
Karamouzis, M. V., Konstantinopoulos, P. A., Papavassiliou, A. G., Targeting MET as a strategy to overcome crosstalk-related resistance to EGFR inhibitors (2009) Lancet Oncol, 10, pp. 709-717
Zhao, X., Weir, B. A., Laframboise, T., Lin, M., Beroukhim, R., Garraway, L., Homozygous deletions and chromosome amplifications in human lung carcinomas revealed by single nucleotide polymorphism array analysis (2005) Cancer Res, 65, pp. 5561-5570
Sharma, S. V., Bell, D. W., Settleman, J., Haber, D. A., Epidermal growth factor receptor mutations in lung cancer (2007) Nat Rev Cancer, 7, pp. 169-181
Shaw, A. T., Yasothan, U., Kirkpatrick, P., Crizotinib (2011) Nat Rev Drug Discov, 10, pp. 897-898
Cui, J. J., Tran-Dube, M., Shen, H., Nambu, M., Kung, P. P., Pairish, M., Structure based drug design of crizotinib (PF-02341066), a potent and selective dual inhibitor of mesenchymal-epithelial transition factor (c-MET) kinase and anaplastic lymphoma kinase (ALK) (2011) J Med Chem, 54, pp. 6342-6363
Oh, S. J., Mosdzianowski, C., Chi, D. Y., Kim, J. Y., Kang, S. H., Ryu, J. S., Fully automated synthesis system of 30-deoxy-30- [18F] fluorothymidine (2004) Nucl Med Biol, 31, pp. 803-809
Ma, P. C., Jagadeeswaran, R., Jagadeesh, S., Tretiakova, M. S., Nallasura, V., Fox, E. A., Functional expression and mutations of c-Met and its therapeutic inhibition with SU11274 and small interfering RNA in non-small cell lung cancer (2005) Cancer Res, 65, pp. 1479-1488
Sohn, H. J., Yang, Y. J., Ryu, J. S., Oh, S. J., Im, K. C., Moon, D. H., [18F] Fluorothymidine positron emission tomography before and 7 days after gefitinib treatment predicts response in patients with advanced adenocarcinoma of the lung (2008) Clin Cancer Res, 14, pp. 7423-7429
Pao, W., Kris, M. G., Iafrate, A. J., Ladanyi, M., Janne, P. A., Wistuba, I. I., Integration of molecular profiling into the lung cancer clinic (2009) Clin Cancer Res, 15, pp. 5317-5322
Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3 '-Deoxy-3 '-[F-18]-Fluorothymidine Positron Emission Tomography
Purpose: MET amplification is one of the mechanisms underlying acquired resistance to EGFR tyrosine kinase inhibitors (TKI) in non-small cell lung cancer (NSCLC). Here, we tested whether 3'-deoxy-3'-[F-18]-fluorothymidine ([F-18]FLT) positron emission tomography/computerized tomography (PET/CT) can detect MET-mediated resistance to EGFR TKIs and monitor the effects of MET inhibitors in NSCLC. Experimental Design: H1993 and H820 NSCLC cells with high and low levels of MET amplification, respectively, and HCC827-expressing MET, but without gene amplification, were tested for the effects of MET inhibitors on the EGFR pathway and proliferation both in vitro and in vivo. Nude mice bearing NSCLCs with and without MET amplification were subjected to [F-18]FLT PET/CT before and after treatment with crizotinib or erlotinib (50 mg/kg and 100 mg/kg p.o. for 3 days). Results: H1993 cells showed high responsiveness to MET inhibitors and were resistant to erlotinib. Conversely, HCC827 cells showed high sensitivity to erlotinib and were resistant to MET inhibitors. Accordingly, H1993 tumors bearing MET amplification showed a mean reduction in [F-18]FLT uptake of 28% and 41% after low-and high-dose treatment with crizotinib for 3 days, whereas no posttherapy changes of [F-18]FLT uptake were observed in HCC827 tumors lacking MET amplification. Furthermore, a persistently high [F-18]FLT uptake was observed in H1993 tumors after treatment with erlotinib, whereas HCC827 tumors showed up to 39% reduction of [F-18]FLT uptake following erlotinib treatment. Imaging findings were confirmed by Ki67 immunostaining of tumor sections. Conclusions: [F-18]FLT PET/CT can detect MET-mediated resistance to EGFR TKIs and its reversal by MET inhibitors in NSCLC. (C)2014 AACR.
Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3 '-Deoxy-3 '-[F-18]-Fluorothymidine Positron Emission Tomography
Monitoring Reversal of MET-Mediated Resistance to EGFR Tyrosine Kinase Inhibitors in Non-Small Cell Lung Cancer Using 3 '-Deoxy-3 '-[F-18]-Fluorothymidine Positron Emission Tomography
Kim YH, Shin SW, Pellicano R, Fagoonee S, Choi IJ, Kim YI, Park B, Choi JM, Kim SG, Choi J, Park JY, Oh S, Yang HJ, Lim JH, Im JP, Kim JS, Jung HC, Ponzetto A, Figura N, Malfertheiner P, Choi IJ, Kook MC, Kim YI, Cho SJ, Lee JY, Kim CG, Park B, Nam BH, Bae SE, Choi KD, Choe J, Kim SO, Na HK, Choi JY, Ahn JY, Jung KW, Lee J, Kim DH, Chang HS, Song HJ, Lee GH, Jung HY, Seta T, Takahashi Y, Noguchi Y, Shikata S, Sakai T, Sakai K, Yamashita Y, Nakayama T, Leja M, Park JY, Murillo R, Liepniece-karele I, Isajevs S, Kikuste I, Rudzite D, Krike P, Parshutin S, Polaka I, Kirsners A, Santare D, Folkmanis V, Daugule I, Plummer M, Herrero R, Tsukamoto T, Nakagawa M, Kiriyama Y, Toyoda T, Cao X, Corral JE, Mera R, Dye CW, Morgan DR, Lee YC, Lin JT, Garcia Martin R, Matia Cubillo A, Lee SH, Park JM, Han YM, Ko WJ, Hahm KB, Leontiadis GI, Ford AC, Ichinose M, Sugano K, Jeong M, Park JM, Han YM, Park KY, Lee DH, Yoo JH, Cho JY, Hahm KB, Bang CS, Baik GH, Shin IS, Kim JB, Suk KT, Yoon JH, Kim YS, Kim DJ * Helicobacter pylori Eradication for Prevention of Metachronous Recurrence after Endoscopic Resection of Early Gastric Cancer(297 views) N Engl J Med (ISSN: 0028-4793, 0028-4793linking, 1533-4406electronic), 2015 Jun; 30642104201566393291: 749-756. Impact Factor:59.558 ViewExport to BibTeXExport to EndNote